Brokerages Set OvaScience Inc. (NASDAQ:OVAS) PT at $8.00
Shares of OvaScience Inc. (NASDAQ:OVAS) have earned an average rating of “Hold” from the five brokerages that are currently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $8.00.
Several research analysts have recently commented on the stock. Zacks Investment Research lowered shares of OvaScience from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of OvaScience in a research note on Thursday, June 22nd. Credit Suisse Group reissued an “underperform” rating and issued a $1.00 price objective on shares of OvaScience in a research note on Tuesday, April 18th. Finally, HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of OvaScience in a research note on Friday, May 12th.
TRADEMARK VIOLATION NOTICE: This article was first posted by Daily Political and is the property of of Daily Political. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.dailypolitical.com/2017/08/07/brokerages-set-ovascience-inc-nasdaqovas-pt-at-8-00.html.
Shares of OvaScience (NASDAQ OVAS) traded up 3.82% during midday trading on Friday, reaching $1.63. 359,818 shares of the company were exchanged. The firm has a 50-day moving average of $1.52 and a 200 day moving average of $1.51. The firm’s market capitalization is $58.13 million. OvaScience has a 52 week low of $1.25 and a 52 week high of $8.98.
OvaScience (NASDAQ:OVAS) last announced its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.45) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.47) by $0.02. The company had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.09 million. OvaScience had a negative net margin of 16,132.47% and a negative return on equity of 69.13%. OvaScience’s revenue was down 55.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.62) earnings per share. On average, equities research analysts expect that OvaScience will post ($1.67) EPS for the current year.
A number of hedge funds have recently modified their holdings of the stock. FMR LLC boosted its stake in shares of OvaScience by 1.3% in the fourth quarter. FMR LLC now owns 5,340,442 shares of the biotechnology company’s stock valued at $8,171,000 after buying an additional 66,400 shares during the period. Northern Capital Management LLC boosted its stake in shares of OvaScience by 92.6% in the first quarter. Northern Capital Management LLC now owns 91,865 shares of the biotechnology company’s stock valued at $172,000 after buying an additional 44,175 shares during the period. UBS Asset Management Americas Inc. purchased a new stake in shares of OvaScience during the first quarter valued at $107,000. GMT Capital Corp boosted its stake in shares of OvaScience by 43.6% in the first quarter. GMT Capital Corp now owns 757,114 shares of the biotechnology company’s stock valued at $1,416,000 after buying an additional 229,719 shares during the period. Finally, KCG Holdings Inc. purchased a new stake in shares of OvaScience during the first quarter valued at $375,000. 63.54% of the stock is currently owned by hedge funds and other institutional investors.
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.
Receive News & Ratings for OvaScience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.